Democracy in Action
After a contentious first meeting regarding regulation, it looks like Cambridge has gone back to the drawing board. As Steve Annear reports for Boston Magazine:
Andrea Jackson, chairwoman of the city’s License Commission, said the department’s executive director would do a “complete rewrite” of a proposal floated by the city earlier this month that set off a heated debate between fans of Uber’s on-demand car services, and drivers from the taxi industry that are under strict guidelines regulated by lawmakers. “We are going to be looking to see what others states and cities have done [with services like Uber], and it will essentially be a complete rewrite of the earlier draft,” said Jackson. “The first draft was essentially just that. It was, ‘hey, let’s have a discussion about it, what do you think.’”
Ah yes, the tried and true "Throw a bunch of stuff against the wall and see what sticks and what causes a bunch of hashtag outrage" method of regulation. Works every time. Discuss
So simple, Fred Flintstone could do it
Bedrock Data wants to simplify data synchronization between applications
From left: Adrian Mott, Taylor Barstow, Benjamin Smith, and John Marcus of Bedrock Data.
Bedrock Data was born as a "nights and weekends" project at HubSpot, the Cambridge digital marketing firm. Bedrock's founders observed how complicated it was to craft connections between various software-as-a-service applications so that data from one could be synchronized with another. While still working at HubSpot, they incorporated Bedrock as a company in mid-2012 so they could start accepting credit cards for the service they'd built — focused on simplifying the process of building those links between applications. But Bedrock's founders didn't depart HubSpot until last year, when they were convinced that their new venture's revenues could support them. Read More
Exuberance interrupted
IPO window shuts for two Massachusetts biotech companies
(Map graphic courtesy of Boston.com)

Ten Massachusetts biotech companies have gone public so far in 2014, a record number for any one year. But the next two contenders in line— who were expected to complete initial public offerings this week — did not make it through the IPO window amid an apparent glut of biotech IPO supply nationally.

Read More